News from the AI & ML world
DeeperML - #aidrugdiscovery
|
@www.infoq.com
// 42d
Google DeepMind has unveiled TxGemma, an AI designed to improve drug discovery and clinical trial predictions. TxGemma, built upon the Gemma model family, aims to streamline the drug development process and accelerate the creation of new treatments. This announcement comes as Isomorphic Labs, an Alphabet spinout, secured $600 million in funding to further develop its AI drug design engine, which reduces manual labor and speeds up drug development.
Isomorphic Labs' engine uses AI to design small molecules with therapeutic applications, predicting their effectiveness in attaching to disease-causing proteins and mapping properties like solubility. This is powered by models like Google's AlphaFold 3, which can predict the shape of proteins, DNA, and RNA, crucial for drug development. The funding will accelerate Isomorphic Labs' research and development efforts, expand its team, and advance its programs, including those focused on oncology and immunology, toward clinical development.
Share:
References :
Classification:
Scott Nover@GZERO Media
// 42d
Isomorphic Labs, a Google DeepMind spinoff, has secured $600 million in its first external funding round to boost its AI-driven drug discovery efforts. The funding round was led by Thrive Capital, with participation from GV and Alphabet, Isomorphic Labs’ existing investor. This significant investment highlights the growing confidence in the potential of AI to revolutionize pharmaceutical research.
The funds will be used to advance Isomorphic's AI drug design engine and therapeutic programs, with a focus on oncology and immunology. The company aims to accelerate the development of new treatments by applying artificial intelligence to the drug development process. Their key technology, AlphaFold 3, developed with Google DeepMind, predicts molecular structures with unprecedented precision. Isomorphic Labs already has collaborations with pharmaceutical giants such as Eli Lilly and Novartis. Founder and CEO of Isomorphic Labs, Sir Demis Hassabis, stated that the funding will "further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.”
Share:
References :
Classification:
Maria Deutscher@AI ? SiliconANGLE
// 43d
Isomorphic Labs, an Alphabet spinout focused on AI-driven drug design, has secured $600 million in its first external funding round. The investment, led by Thrive Capital with participation from Alphabet and GV, will fuel the advancement of Isomorphic Labs' AI drug design engine and therapeutic programs. The company aims to leverage artificial intelligence, including its AlphaFold technology, to revolutionize drug discovery across various therapeutic areas, including oncology and immunology. This funding is expected to accelerate research and development efforts, as well as facilitate the expansion of Isomorphic Labs' team with top-tier talent.
Isomorphic Labs, founded in 2021 by Sir Demis Hassabis, seeks to reimagine and accelerate drug discovery by applying AI. Its AI-powered engine streamlines the design of small molecules with therapeutic applications and can predict the effectiveness of a small molecule's attachment to a protein. The company's software also eases other aspects of the drug development workflow. Isomorphic Labs has already established collaborations with pharmaceutical companies like Eli Lilly and Novartis, and the new funding will support the progression of its own drug programs into clinical development.
Share:
References :
Classification:
|
BenchmarksBlogsResearch Tools |